Detail of "2746-81-8"
- CAS Number:
- 2746-81-8
- Name:
Heptanoic acid,2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester
- Molecular Structure:
![Molecular Structure of 2746-81-8 (Heptanoic acid,2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester)](http://www.lookchem.com/300w/2010/0620/2746-81-8.jpg)
- Formula:
- C29H38 F3 N3 O2 S
- Molecular Weight:
- 549.76
- Synonyms:
- Heptanoicacid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester (7CI,8CI); 1-Piperazineethanol,4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-, heptanoate (ester) (8CI);4-[3-(2-Trifluoromethyl-10-phenothiazinyl)propyl]-1-piperazineethanolenanthate; Fluphenazine enanthate; Moditen enanthate; Prolixin enanthate; SQ16,114; SQ 16144
- Density:
- 1.181g/cm3
- Boiling Point:
- 629.4°Cat760mmHg
- Flash Point:
- 334.4°C
- Safety:
- Poison by intravenous, intramuscular, intraperitoneal, and subcutaneous routes. Human systemic effects by subcutaneous route: muscle weakness; by intramuscular route: musculo-skeletal changes. When heated to decomposition it emits very toxic fumes of F−, SOx, and NOx. Details
Heptanoic acid,2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers
will soon contact you!
*Required Fields
Reference
- Fluphenazine-induced acute and tardive dyskinesias in monkeys
- Fluphenazine-induced acute and tardive dyskinesias in monkeys. Kovacic, Beverly; Domino, Edward F. (Div. Pharmacol., Lafayette Clin., Detroit, MI 48207, USA). Psychopharmacology (Berlin), 84(3), 310-14 (English) 1984. CODEN: PSCHDL. ISSN: 0033-3158. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Five Cebus apella monkeys were treated with biweekly injections of fluphenazine enanthate [2746-81-8] (0.1-3.2 mg/kg, i.m.). Three of these completed 1 full year of treatment, one injured its leg after 6 mo of treatment and was killed, and another died of unknown causes after 9 mo of treatment. All monkeys displayed abnormal movements corresponding to the early appearing extrapyramidal symptoms of neuroleptic-treated patients. These consisted initially of slowing or absence of volitional movement, trembling of the hands, trembling of the entire body, and general drowsy behavior. As treatment continued, a variety of abnormal postures and movements appeared after each injection that were not exacerbated by drug withdrawal and, as tested at the end of the year, could be abolished or prevented with benztropine mesylate [132-17-2] (0.2-0.5 mg/kg i.m.). The 3 monkeys that completed 1 yr of treatment with fluphenazine were then withdrawn from the drug. After withdrawal, all 3 developed movements similar in appearance to those of patients with tardive dyskinesia (TD). Reinstitution of fluphenazine treatment, as tested in one monkey, abolished all movements resembling TD.
- Fluphenazine and fluphenazine decanoate plasma levels of humans
- Fluphenazine and fluphenazine decanoate plasma levels of humans. Curry, S. H. (Dep. Pharmacol. Ther., London Hosp. Med. Coll., London, Engl.). Klin. Pharmakol. Langzeitneuroleptika, Alpenl. Psychiatr.-Symp., 1st, Meeting Date 1976, 75-83. Edited by: Kryspin-Exner, Kornelius; Haase, H. J.; Hinterhuber, H. Schattauer: Stuttgart, Ger. (German) 1977. CODEN: 37PFAC. DOCUMENT TYPE: Conference; General Review CA Section: 1 (Pharmacodynamics) A review with 7 refs. on the pharmacokinetics of fluphenazine (I) [69-23-8], I-2HCl [146-56-5], I decanoate [5002-47-1], and I enanthate [2746-81-8] in plasma and urine after oral and i.m. administration.